US Material Events SEC 8-K Filings — June 30, 2026

30-06-2026

Nexscient, Inc. announced the resignation of COO Tarek Shoufani effective June 30, 2026, who will remain on the board as a non-employee director. The company also appointed Jaime Fanlo as an independent director effective July 1, 2026, and granted performance-based RSU awards of 250,000 shares each to Shoufani, Fanlo, and Eric Manlunas, with vesting tied to market capitalization thresholds over a 10-year period. No cash compensation is provided to non-employee directors.

• · Mr. Shoufani's resignation was not due to any disagreement with the company.
• · Jaime Fanlo holds a BA in Political Economy from the University of Asia and the Pacific and a Juris Doctor from Ateneo de Manila School of Law (2007).
• · Fanlo has over 18 years of cross-border experience in corporate governance, private equity, and commercial law.
• · Fanlo is a current stockholder of the company and serves as a director of subsidiaries Crestview BPO and Flipside AI.
• · The Board determined Fanlo qualifies as an independent director under Nasdaq and SEC standards; he has not been assigned to any board committee.
• · No cash retainer, meeting fee, or cash stipend is paid to non-employee directors; compensation is solely performance-based RSU awards plus expense reimbursement and indemnification.
• · RSU awards are granted as standalone inducement awards, not under any equity incentive plan.
• · Unvested RSUs are forfeited if performance thresholds are not met within 10 years; immediate forfeiture occurs upon termination for cause.
• · Accelerated vesting is provided in connection with a change of control.

30-06-2026

Rani Therapeutics appointed Nicholas M. Maestas as CFO effective June 29, 2026, replacing Svai Sanford. Maestas receives a $500,000 base salary, 75% target bonus, and a 2,000,000-share option grant under a new 2026 Equity Inducement Plan that reserves 5,500,000 shares. The company’s board approved the inducement plan on June 28, 2026, and stockholder approval is not required under Nasdaq Rule 5635(c)(4).

• · The Inducement Plan was approved by the Board on June 28, 2026, without stockholder approval, as permitted by Nasdaq Rule 5635(c)(4).
• · Maestas served as CFO and Head of Corporate Strategy at Tempest Therapeutics from Jan 2025 to Jun 2026, and previously as VP of Finance and Strategy from Jul 2021.
• · He holds a B.A. in Molecular and Cell Biology from UC Berkeley and an MBA from Wharton.

30-06-2026

Creative Realities, Inc. announced the pricing of a $12 million underwritten public offering, issuing 2,528,571 shares of common stock at $3.50 per share and pre-funded warrants for up to 900,000 shares at $3.49 per warrant. The company expects to use net proceeds for working capital, debt paydown, and potential acquisitions, with the offering set to close around June 30, 2026. The company's performance and future outlook remain subject to risks including integration of the recently acquired CDM business and ability to continue as a going concern.

• · The company granted the underwriter a 30-day option to purchase up to an additional 428,614 shares at the public offering price, less underwriting discounts and commissions.
• · Proceeds from the offering will be used for working capital, general corporate purposes, debt paydown, and potential acquisitions.
• · Craig-Hallum is acting as sole managing underwriter.
• · The shelf registration statement (Form S-3, 333-296498) has been declared effective by the SEC.
• · The company cautioned about risks including integration of the recently acquired Cineplex Digital Media business, ability to realize anticipated synergies, and the risk of not being able to continue as a going concern.
• · No specific financial performance metrics (revenue, growth, etc.) were provided in this filing.

30-06-2026

Eos Energy Enterprises entered into a binding amended and restated term sheet with Cerberus Capital Management and Hudson Bay Capital to form a joint venture (Frontier Power USA Parent, LLC). Cerberus will contribute $100 million for Class A-2 Units and receive warrants for 20,017,772 shares, while Hudson Bay will contribute $50 million for Class C Units and receive warrants for 10,008,886 shares. Eos will fund its contribution via a $150 million rights offering at $5.481 per unit, but the transactions are subject to DOE consent and other conditions, with no guarantee of completion.

• · The JV Company board will have 7 members: 4 appointed by Cerberus and up to 3 by Eos (subject to ownership thresholds).
• · Day-to-day oversight of JV development projects will be delegated to a Cerberus affiliate via a management services agreement.
• · HBC has an exchange right for Class C Units into Eos common shares: before Dec 31, 2026, up to 50% at $15.00/share, up to 75% at $17.50/share, up to 100% at $20.00/share; after Dec 31, 2026, at the rights offering price.
• · Liquidation distributions follow a waterfall: first to Cerberus and Hudson Bay for return of invested capital (excluding Cerberus's pre-closing contribution), then to Eos, then to Cerberus for pre-closing contribution, then pro rata until 10% pre-tax IRR compounded quarterly, then to preferred and incentive unit holders.
• · The rights offering is limited to $150 million; Cerberus consent required for any excess.
• · Conditions to closing include DOE consent and execution of a Commercial Framework Guidelines.
• · RO Warrants and the Cerberus/HBC warrants each expire 10 years after closing.
• · RO Warrants and HBC/Cerberus warrants are exercisable on a cashless basis.

30-06-2026

Sadot Group Inc. sold 100% of its subsidiary Sadot Latam LLC to Dream America Marketing Services, Ltd for $1,000 cash plus a 27.5% profit-sharing payment on collected receivables. The transaction deconsolidates Sadot Latam from Sadot Group's financial statements, with the company evaluating the accounting impact for the quarter ending June 30, 2026. The sale includes assets such as a $250,000 Citizens Bank deposit and partial interests in certain receivables and litigation proceeds, but the nominal cash consideration and reliance on uncertain collections highlight a potential divestiture of a distressed or non-core asset.

• · The SPA is governed by New York law with disputes resolved via AAA arbitration in New York.
• · The seller agreed to provide legal support for six months post-closing for existing litigation and disputes.
• · The company expects to reflect deconsolidation effects in its Q2 2026 financial statements.
• · The financial effects of deconsolidation are preliminary, unaudited, and subject to change.

30-06-2026

SSR Mining Inc. completed the sale of its 80% ownership stake in the Çöpler mine and related properties in Türkiye to Cengiz Holding A.Ş. for approximately $1.49 billion in cash. The transaction, which closed on June 24, 2026, results in the removal of Çöpler's financial results from continuing operations. Pro forma financial statements show that on a continuing operations basis, net income attributable to SSR Mining shareholders would have been $529.5 million for 2025 (up from $395.8 million as reported), $158.8 million for 2024 (versus a net loss of $261.3 million as reported), and $75.6 million for 2023 (versus a net loss of $98.0 million as reported). However, the pro forma adjustments also include a $3.1 million other expense and a $0.8 million tax benefit in 2025, and the removal of Çöpler's revenue contributions in 2024 and 2023.

• · The transaction closed on June 24, 2026, pursuant to a Share Purchase Agreement dated March 24, 2026.
• · Pro forma adjustments for 2025 include a $3.1 million other expense and a $0.8 million tax benefit.
• · Çöpler's results were reported as discontinued operations from Q1 2026.
• · Pro forma basic EPS for continuing operations: $2.61 (2025), $0.78 (2024), $0.37 (2023).
• · Pro forma diluted EPS for continuing operations: $2.46 (2025), $0.76 (2024), $0.37 (2023).

30-06-2026

Angel Studios amended its merger agreements to acquire Tuttle Twins Show (TTS) and Toothy Cow Productions (TCP), extending the outside closing date to October 31, 2026. The company has already provided $11.7 million in operational funding to TTS and $11.9 million to TCP, with conversion terms if the acquisitions fail. Related parties own 41.6% of TTS units and 2.4% of TCP units, highlighting significant insider involvement.

• · The A&R TTS Merger Agreement eliminated the requirement for a showrunner agreement with Daniel Harmon as a closing condition.
• · The A&R TCP Merger Agreement replaced the IP assignment agreement condition with a requirement for a new TCP A&R License Agreement.
• · Under the revised TCP Merger structure, Angel TCP Merger Sub will survive and TCP will cease to exist.
• · If the TTS acquisition fails, operational funding since September 10, 2025 converts to preferred units at $1.16 per unit.
• · If the TCP acquisition fails, operational funding converts to TCP Class B Preferred Units at $1.50 per unit plus a warrant to purchase TCP Common Units at a nominal strike price for each two Class B preferred units received.

30-06-2026

AMASS Brands Inc. entered into Amendment No. 2 to its SAFE agreement with AFTERDREAM, Inc., increasing the Purchase Amount from $1,535,000 to $1,735,000 (an additional $200,000 investment by the Company). The Post-Money Valuation Cap remains unchanged at $7,500,000, and all other material terms of the SAFE remain in effect. The amendment was executed on June 25, 2026, and disclosed via Form 8-K on June 30, 2026.

• · The SAFE was originally entered into on June 16, 2026, with Amendment No. 1 dated June 17, 2026.
• · The Second Amendment was executed on June 25, 2026, and the Form 8-K was signed on June 29, 2026.
• · The SAFE includes conversion mechanics upon an Equity Financing, Liquidity Event, or Dissolution Event.
• · Portions of the exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

30-06-2026

Quantum Computing Inc. filed an 8-K announcing an amendment to its Certificate of Incorporation to increase authorized shares from 310,000,000 to 460,000,000, consisting of 450,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock. The amendment was approved by the Board of Directors and stockholders. No financial impact or performance metrics were disclosed.

• · The amendment increases total authorized shares from 310,000,000 to 460,000,000.
• · Common stock par value remains $0.0001 per share.
• · Preferred stock par value remains $0.0001 per share.
• · The amendment was adopted under Section 242 of the Delaware General Corporation Law.
• · Stockholders approved the amendment at a meeting called in accordance with Section 222.

30-06-2026

Magnachip Semiconductor announced the appointment of Chae Lee as Chief Executive Officer, effective July 1, 2026, succeeding Camillo Martino who served as Interim CEO since August 2025. Martino will continue as Chairman of the Board. Lee brings over 30 years of semiconductor industry experience, most recently as CEO of Tagore Technology, and is expected to join the Board after his appointment.

• · Lee's appointment is effective July 1, 2026.
• · Martino served as Interim CEO since August 2025.
• · Lee previously served as CEO of Tagore Technology, a provider of GaN semiconductor solutions for RF and Power applications.
• · Lee also held senior leadership positions at Insyte Systems, NXP Semiconductors, and Maxim Integrated Products.
• · Magnachip has about 45 years of operating history and owns a substantial number of registered patents and pending applications.

30-06-2026

Analysis unavailable

30-06-2026

Pacira BioSciences agreed to divest its iovera° business to Zimmer Biomet for up to $140 million, with $70 million upfront and up to $70 million in potential revenue-based milestones through 2031. The deal supports Pacira's 5x30 strategy and transition into an innovative biopharmaceutical company, while the companies will collaborate on advancing the spasticity program. However, the transaction is subject to customary closing conditions and is not expected to close until Q3 2026, and the milestone payments are contingent on future revenue performance, introducing uncertainty.

• · Pacira intends to use upfront net proceeds to pay down its senior secured revolving credit facility.
• · The parties will enter into a transition services agreement to support a smooth transition.
• · iovera° is an FDA-cleared, drug-free cryoneurolysis device for pain relief, including osteoarthritis knee pain for up to 90 days.
• · Pacira retains its other commercial-stage non-opioid treatments: EXPAREL and ZILRETTA.
• · Pacira's pipeline includes PCRX-201 (gene therapy for osteoarthritis) in Phase 2 development.
• · Closing expected in Q3 2026, subject to customary conditions.

30-06-2026

Palvella Therapeutics appointed Matthew Pauls as a Class I director on June 29, 2026, expanding the board from seven to eight members. Mr. Pauls brings extensive biopharmaceutical leadership experience, including serving as CEO of Savara, Inc. and previously leading Strongbridge Biopharma through its IPO and commercialization. He received an option to purchase 6,000 shares vesting over 36 months, with no immediate financial impact or related party transactions disclosed.

• · Mr. Pauls served as Lead Independent Director of Soleno Therapeutics from 2024 until its $2.9 billion acquisition by Neurocrine Biosciences in 2026.
• · Mr. Pauls holds a B.S., an M.B.A. from Central Michigan University, and a J.D. from Michigan State University College of Law.
• · The Board determined Mr. Pauls is independent under Nasdaq listing rules.
• · No arrangements or understandings exist between Mr. Pauls and any other person regarding his selection as a director.
• · Mr. Pauls does not have any family relationships with any of the Company’s directors or executive officers.

30-06-2026

The filing reports the departure of a director/officer and the appointment of a new director/officer, but no specific names, positions, or reasons are disclosed. No financial metrics, compensation details, or scheduled events are provided. The filing is informational with no material quantitative data to assess.

• · Filing date: June 30, 2026
• · AccNo: 0001903596-26-000268
• · Company: Graphene & Solar Technologies Ltd
• · Event type: Officer Change
• · Items reported: 5.02, 8.01, 9.01
• · No specific names, positions, or reasons for departure/appointment disclosed
• · No financial data, compensation, or forward-looking guidance provided

30-06-2026

Launch Two Acquisition Corp. (LPBBU) has entered into a definitive Business Combination Agreement to acquire NuCube Energy, Inc., a developer of high-temperature solid-state nuclear fission modular microreactors, through a merger of its wholly-owned subsidiary Tesseract Merger Sub Inc. with and into NuCube. The transaction, valued at an implied enterprise value of approximately $850 million, is expected to close in Q4 2026, subject to regulatory and stockholder approvals. However, the filing notes that NuCube has not yet generated revenue and reported a net loss of $12.3 million for the fiscal year ended December 31, 2025, highlighting the pre-revenue stage of the target company.

• · The SPAC will re-domicile from the Cayman Islands to Delaware prior to the merger.
• · Sponsor and certain stockholders have agreed to lock-up periods of 180 days post-closing, with early release possible if stock price reaches $12.50 for 20 trading days within 30 days.
• · The transaction includes an earnout provision for NuCube stockholders based on future performance milestones.
• · NuCube has not yet generated any revenue and is in a pre-revenue stage.
• · The merger is intended to qualify as a tax-free reorganization under Section 368 of the Internal Revenue Code.

30-06-2026

First Financial Corp (THFF) entered into new employment agreements with three senior officers (CFO, CCO, CLO) effective July 1, 2026, with base salaries of $387,131 for McHargue, $317,228 for Panagouleas, and $319,307 for Franklin. The 24-month agreements include non-compete and change-in-control severance provisions (2x base salary plus bonus and benefits), but no financial results or performance metrics were disclosed.

• · Agreements effective July 1, 2026, with initial term of 24 months, renewable annually at compensation committee's discretion.
• · Non-compete radius: 75 miles (50 miles if terminated without cause or for good reason) from Terre Haute for McHargue & Panagouleas, from Bloomington for Franklin.
• · Severance for termination without cause (not within 12 months of change of control) equals base salary plus bonuses through the end of the current term plus cash reimbursements for benefits.
• · Change-in-control severance: 2.00 times (base salary + prior year bonuses + benefits cost for 2 years), subject to 280G excise tax cutback if advantageous.
• · Agreements include confidentiality and non-solicitation provisions.

30-06-2026

ZW Data Action Technologies Inc. (CNET) announced that its BVI subsidiary, CNET Technology Limited, will acquire an 8.0% equity interest in MARGO ASIA LIMITED from AFFIRM MISSION LIMITED for a total consideration of $600,000, comprising $474,000 in cash and 180,000 shares of CNET common stock valued at $0.70 per share ($126,000). The acquisition is subject to customary closing conditions.

• · The Purchaser is CNET Technology Limited, a wholly-owned BVI subsidiary of ZW Data Action Technologies Inc.
• · The Seller is AFFIRM MISSION LIMITED, a BVI company.
• · The target entity is MARGO ASIA LIMITED, also a BVI company.
• · The stock consideration is valued at $0.70 per share.
• · The acquisition agreement was entered into on June 26, 2026.
• · The filing was made on June 30, 2026.

30-06-2026

Ecovyst Inc. entered into a Fourth Amendment to its Term Loan Credit Agreement to secure $100M in incremental term loans, primarily to finance the acquisition of INEOS Calabrian Holdings Corp. and INEOS Calabrian Corporation Canada Inc. The amendment, effective June 30, 2026, adds a new $100M incremental term facility that is fungible with existing initial term loans. The acquisition is being executed through wholly owned subsidiaries pursuant to a Share Purchase Agreement dated May 1, 2026.

• · The Fourth Amendment was entered into on June 30, 2026, and amends the Existing Credit Agreement dated June 9, 2021, as previously amended in February 2023, June 2024, and January 2025.
• · The 2026 Incremental Term Loans are incurred under clause (c) of the definition of 'Incremental Cap'.
• · The proceeds will be used for purposes set out in Section 5.11(b) of the Amended Credit Agreement.
• · The amendment was arranged by a syndicate including Citi, BofA Securities, UBS Securities, Goldman Sachs, Deutsche Bank, KeyBanc Capital Markets, and Truist Securities.
• · Conditions to effectiveness included delivery of legal opinions, secretary's certificates, good standing certificates, and a borrowing request.

30-06-2026

Cuentas Inc. entered into an Amended and Restated Warrant Agency Agreement on June 29, 2026, extending the expiration date of its outstanding publicly traded warrants from June 30, 2026 to September 30, 2026. The agreement also allows the Board of Directors to voluntarily reduce the exercise price (currently $55.90 per share after a reverse stock split) and proportionately increase the number of shares purchasable. The extension aims to encourage warrant exercise to provide funds for operations as the company restructures its business and seeks financing.

• · The warrants were originally issued in February 2021 as part of an underwritten offering of units, each consisting of one share of common stock and one warrant.
• · The exercise price increased from $4.30 to $55.90 due to a 1-for-13 reverse stock split completed on March 24, 2023.
• · The company has applied to have its common stock and warrants listed on OTCQB.
• · The company has restructured its business and entered into a joint venture with World Mobile, LLC and World Mobile Media Group, LLC.

30-06-2026

Analysis unavailable

30-06-2026

MarineMax refinanced its $1.49 billion senior secured credit facilities, reducing borrowing costs, extending the maturity profile to June 2031, and expanding the revolving credit facility from $100 million to $150 million to enhance financial flexibility. The refinancing includes a $950 million floor plan line, a $302.5 million term loan, and an $85 million delayed draw mortgage facility (with $35 million drawn). While the company highlights improved terms and lender confidence, the filing does not disclose the prior borrowing costs or provide quantitative comparisons of interest savings, and the mortgage facility was reduced from $100 million to $85 million.

• · The new credit facilities mature in June 2031, extending the debt maturity profile by five years.
• · The mortgage facility was reduced from $100 million to $85 million, with only $35 million drawn.
• · M&T Bank acted as Administrative Agent and Joint Lead Arranger; Wells Fargo Commercial Distribution Finance served as Joint Lead Arranger and Floor Plan Agent.
• · MarineMax has over 120 locations worldwide, including over 70 dealerships and 65 marina and storage facilities.

30-06-2026

Skillsoft Corp. held its 2026 Annual Meeting on June 25, 2026, where stockholders approved the Second Amendment to the 2020 Omnibus Incentive Plan, increasing authorized shares by 550,000 to 4,305,658. The meeting also saw the election of three Class II directors and advisory approval of executive compensation. However, the Second Amendment received only 81.6% of votes cast in favor, with 18.4% against, indicating notable dissent.

• · The Second Amendment was approved with 5,191,165 votes for, 1,170,074 against, and 4,082 abstentions, plus 1,093,722 broker non-votes.
• · Advisory vote on executive compensation: 5,491,157 for, 868,427 against, 5,737 abstentions.
• · Ratification of Ernst & Young LLP: 7,452,117 for, 1,554 against, 5,372 abstentions (no broker non-votes).
• · Election results: Michael S. Klein received 5,903,836 votes for and 461,485 withheld; Denis Nikolaev 6,316,961 for and 48,360 withheld; Arthur Gilliland 6,322,093 for and 43,228 withheld.

30-06-2026

Sera Prognostics appointed Mark Capone, former CEO of Myriad Genetics, to its Board of Directors effective July 1, 2026. Capone brings over 40 years of diagnostics and life sciences leadership, including expertise in commercializing complex diagnostic products and navigating reimbursement environments, which the company expects will support adoption of its PreTRM test. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons are available.

• · Mark Capone served as CEO of Myriad Genetics, leading its transformation into a precision medicine organization and expanding its molecular diagnostics portfolio.
• · Capone held senior leadership roles at Myriad over 17 years, including President and COO.
• · Earlier in his career, Capone held leadership positions at Eli Lilly and other healthcare organizations.
• · The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test for spontaneous preterm birth risk prediction in asymptomatic singleton pregnancies.
• · The U.S. earned a D+ grade for preterm birth for the fourth consecutive year (2025 March of Dimes Report Card).
• · Annual healthcare costs for prematurity in the U.S. were estimated at approximately $25 billion for 2016.

30-06-2026

W. P. Carey Inc. priced a $350 million public offering of 5.200% Senior Notes due 2036 at 99.015% of par, with net proceeds intended to repay $350 million of 4.250% Senior Notes due October 2026 and for general corporate purposes. The offering is expected to settle on July 2, 2026, and the new notes carry a higher coupon (5.200%) than the notes being refinanced (4.250%), reflecting higher interest costs. The company maintains a large net lease portfolio of 1,703 properties covering ~185 million square feet as of March 31, 2026.

• · Interest on the new Notes will be paid semi-annually on March 15 and September 15, beginning March 15, 2027.
• · Joint book-running managers: Wells Fargo Securities, RBC Capital Markets, U.S. Bancorp Investments, and BBVA Securities.
• · The company's portfolio includes 1,703 net lease properties covering ~185 million square feet as of March 31, 2026.
• · Offices located in New York, London, Amsterdam, and Dallas.
• · The company focuses on single-tenant industrial, warehouse, and retail properties in the U.S. and Europe under long-term net leases with built-in rent escalations.

30-06-2026

Aptevo Therapeutics Inc. (APVO) announced it has been awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO451, its novel Nectin-4-targeted trispecific immunotherapy for solid tumors. The grant provides external validation of the program, which is advancing toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027. No negative or flat financial metrics were reported in this filing.

• · APVO451 is a trispecific antibody-like immunotherapy targeting nectin-4, CD40, and CD3.
• · The grant supports preclinical studies and development work toward IND-enabling studies.
• · APVO451 incorporates Aptevo's CRIS-7-derived CD3 binding domain, the same platform used in mipletamig.
• · The program is designed to focus immune activation within the tumor microenvironment and reduce risk of systemic immune activation.
• · Aptevo's pipeline includes two clinical candidates and multiple preclinical programs.

30-06-2026

Stabilis Solutions, Inc. filed an 8-K on June 30, 2026, regarding a material agreement (Item 1.01) and a direct financial obligation or off-balance sheet arrangement (Item 2.03). The filing does not disclose specific financial terms or performance metrics.

• · The filing relates to a material agreement and a direct financial obligation or off-balance sheet arrangement.
• · The cover page is provided as an inline XBRL document.

30-06-2026

Frontier Group Holdings extended its credit card affinity agreement with Barclays Bank Delaware through June 30, 2037, and increased its pre-purchased miles facility from $200 million to $375 million. The amendment includes enhanced net compensation and a pre-paid consideration received before June 30, 2026, which was slightly better than anticipated. However, the facility requires payback of any borrowed amounts beginning June 2036 in 12 equal monthly installments, and the actual facility size is subject to semi-annual program requirements.

• · The Seventh Amendment extends the term of the Credit Card Affinity Agreement from December 31, 2029 to June 30, 2037.
• · The pre-purchased miles facility's aggregate maximum increased from $200 million to $375 million, with actual size subject to semi-annual program requirements.
• · Payback of any borrowed amounts under the facility begins June 2036 in 12 equal monthly installments.
• · The amendment also modified certain financial covenants of the facility.
• · The pre-paid consideration was received by Frontier prior to the end of June 2026.

30-06-2026

Main Street Capital Corporation announced an amendment to its revolving credit facility, increasing total commitments from $1.175 billion to $1.240 billion, while maintaining an accordion feature allowing expansion up to $1.860 billion. The amendment also extends the revolving period through June 2030 and the final maturity date to June 2031, with options for up to two additional years subject to lender approval. The facility continues to benefit from a diversified group of 18 lenders.

• · The amendment maintains an expanded accordion feature allowing total commitments up to $1.860 billion on same terms and conditions as existing commitments.
• · The revolving period is extended through June 2030 and final maturity to June 2031.
• · Main Street retains options to extend both the revolving period and final maturity by up to two additional years, subject to lender approval.
• · The facility benefits from a diversified group of 18 lenders.

30-06-2026

Terex Corporation held its 2026 Annual Meeting on June 25, 2026, where stockholders elected 12 directors, approved executive compensation on an advisory basis, ratified KPMG as auditor, and approved the 2026 Omnibus Incentive Plan. All director nominees received strong support, though Sandie O'Connor and David Sachs each had over 2.2 million votes against. The Omnibus Plan was approved with 98,052,459 for and 2,406,094 against.

• · Proposal 1: All directors elected with votes for ranging from 98,169,635 to 100,358,485.
• · Proposal 2: Advisory vote on executive compensation passed with 98,623,406 for, 1,814,075 against.
• · Proposal 3: Omnibus Plan approved with 98,052,459 for, 2,406,094 against.
• · Proposal 4: Ratification of KPMG passed with 106,154,545 for, 90,566 against.
• · Broker non-votes were 5,795,483 for all director elections and proposals 2 and 3.

30-06-2026

Twenty One Capital, Inc. appointed Karl Olsoni as an independent director and to its Audit Committee, effective June 30, 2026. Under the independent director agreement, Olsoni will receive an annual cash retainer of $150,000 and an annual equity award of $150,000 in Class A stock, plus expense reimbursement. The filing does not disclose any financial results or performance metrics, so no positive or negative trends are reported.

• · Olsoni's term expires at the 2027 annual general meeting of shareholders.
• · The equity award vests in full upon grant.
• · Olsoni is prohibited from serving on more than two Board committees simultaneously.
• · The Company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.

30-06-2026

MSP Recovery, Inc. disclosed a letter agreement with Hazel Partners Holdings LLC confirming a series of incremental fundings totaling $8,355,500 to increase the Operational Collection Floor under the existing Credit Agreement, plus an additional $550,000 for legal expenses. The lender also confirmed receipt of approximately $1,300,000 in HC Case Proceeds from property and casualty litigation, with $605,313 granted as collateral. While the additional financing provides liquidity, the reliance on discretionary lender funding and the estimated nature of the HC Case Proceeds introduce uncertainty.

• · The $208,000 funding on June 26, 2026 is at the sole discretion of the Administrative Agent and Lender, and no Event of Default may result from the borrowing.
• · The HC Case Proceeds of approximately $1,300,000 are from property and casualty litigation, with 50% due to Assignor and 50% to Assignee.
• · The $550,000 legal expense funding was provided to MSP Recovery, LLC on April 10, 2025.
• · The Aggregate Operational Collection Floor after all fundings is $8,355,500.
• · The lender reserves all rights under the Credit Agreement and may withhold further funding.

30-06-2026

Envoy Medical terminated its at-the-market (ATM) equity facility effective June 24, 2026, citing confidence in its current capital position. The ATM facility had authorized up to $15 million in share sales. No negative or flat financial metrics were disclosed, and the filing focuses on a strategic reduction of equity dilution risk.

• · The ATM facility termination was effective June 24, 2026.
• · Envoy Medical's common stock trades under NASDAQ: COCH.
• · The Acclaim cochlear implant is an investigational device and received FDA Breakthrough Device Designation in 2019.
• · The Esteem FI-AMEI has been commercially available in the U.S. since 2010.

30-06-2026

Benchmark 2026-V22 Mortgage Trust filed an 8-K on June 30, 2026, reporting that servicing of two whole loans (ONX Industrial Campus and Marriott Savannah Riverfront) has been transferred to a new securitization trust (BBCMS 2026-5C42) under a new pooling and servicing agreement (PSA). The new PSA includes specific fee structures for special servicing, workout, and liquidation, with maximum fees capped at $1,000,000 and minimum fees of $25,000. Property inspection frequency varies based on loan principal balance, with higher-balance loans inspected every 12 months and lower-balance loans every 24 months.

• · The servicing transfer occurred upon issuance of BBCMS 2026-5C42 Certificates on June 24, 2026.
• · The new PSA is dated June 1, 2026.
• · Property inspection frequency: every 12 months for loans with principal balance >= $2,000,000; every 24 months for loans with principal balance < $2,000,000, starting calendar year 2027.
• · The filing amends a prior Form 8-K/A filed May 26, 2026.

30-06-2026

Disc Medicine, Inc. (IRON) amended its loan agreement with Hercules Capital, drawing down $30 million of the Tranche 1-B Advance and restructuring the remaining Tranche 1-C ($50 million) into two tranches: $25 million available through March 31, 2027, and $25 million (Tranche 1-D) available through April 30, 2027. The draw periods for Tranche 2 and Tranche 3 were extended to December 15, 2027 and June 30, 2028, respectively. While the amendment provides additional liquidity and flexibility by pushing the minimum cash covenant test date to July 1, 2028, the Company is incurring additional debt and may face future dilution or cash flow constraints.

• · The original Loan and Security Agreement was dated November 6, 2024.
• · Tranche 2 Advance draw period extended to December 15, 2027.
• · Tranche 3 Advance draw period extended to June 30, 2028.
• · Minimum cash covenant initial testing date moved to July 1, 2028.

30-06-2026

Granite Point Mortgage Trust Inc. (GPMT-PA) entered into the Fifteenth Amendment to its Master Repurchase Agreement with Morgan Stanley Bank, N.A., extending the facility termination date to June 28, 2027, and amending financial covenants. The amendment reduces the minimum Unrestricted Cash requirement to $20 million and sets a minimum Tangible Net Worth of $450 million. No material financial figures were disclosed regarding the size of the facility or current outstanding balances.

• · The amendment deletes definitions for 'Purchased Asset A', 'Purchased Asset B', 'Purchased Asset C', and 'Purchased Asset C Release Payment' from the Master Repurchase Agreement.
• · No Exit Fee shall be due when repurchasing assets to refinance under another facility.
• · Seller's address updated to 1114 Avenue of the Americas, Suite 3020, New York, NY 10036.
• · No Event of Default or Margin Deficit exists as of the amendment date.

30-06-2026

HighPeak Energy, Inc. entered into a Fourth Amendment to its Credit Agreement with Fifth Third Bank and other lenders, effective June 30, 2026. The amendment tightens the Total Net Leverage Ratio covenant from 2.50x to 2.25x for the quarter ending June 30, 2026, and further to 2.00x for quarters beginning September 30, 2026 onward. No material adverse effect has occurred since December 30, 2025, and no defaults are continuing.

• · The amendment was executed on June 30, 2026, and is effective as of the Fourth Amendment Effective Date (June 30, 2026).
• · The Total Net Leverage Ratio covenant steps down from 2.50x (for quarters ending Dec 31, 2025 and Mar 31, 2026) to 2.25x for the quarter ending June 30, 2026, and then to 2.00x for quarters ending September 30, 2026 and thereafter.
• · No Material Adverse Effect has occurred since December 30, 2025.
• · All representations and warranties remain true and correct, and no Default or Event of Default exists.
• · The amendment was consented to by all Guarantors (HighPeak Energy Holdings, LLC; Lazy JJ Properties, LLC; HighPeak Energy Acquisition Corp.; HighPeak Energy Assets, LLC; HighPeak Energy Employees, Inc.) and Lenders (Fifth Third Bank and Texas Capital Bank).

30-06-2026

AquaBounty Technologies, Inc. filed a Certificate of Designation with the Delaware Secretary of State on June 25, 2026, establishing 200,000 shares of Series B Convertible Preferred Stock with a liquidation value of $20.60 per share. The Series B Preferred Stock carries an 18.0% per annum cumulative dividend rate, ranks senior to common stock and junior securities, and is pari passu with the existing Series A Preferred Stock. The filing also includes provisions for conversion, redemption, and voting rights tied to the underlying common stock.

• · Series B Preferred Stock ranks senior to all Junior Securities and pari passu with Series A Preferred Stock.
• · Dividends accrue quarterly at 18.0% per annum on the liquidation value, payable in cash bi-annually on the last day of October and April, unless the Board defers payment.
• · Dividends cannot be settled in Common Stock unless compliant with Nasdaq Listing Rule 5635(d) or stockholder approval is obtained.
• · Upon liquidation or Change of Control, holders may elect cash or non-cash consideration equal to the liquidation value plus all unpaid accrued dividends.
• · Each Series B Preferred Share votes with Series A and Common Stock as a single class, with votes equal to the number of Common Stock shares it is convertible into.
• · The filing was made under Items 1.01, 3.02, 3.03, 5.03, and 9.01 of Form 8-K.

30-06-2026

BlackRock Monticello Debt Real Estate Investment Trust, through its subsidiary BLKM I, LLC, entered into a First Amendment to its Master Repurchase Agreement and Securities Contract with Natixis, New York Branch, dated June 24, 2026. The amendment modifies the existing agreement originally dated May 23, 2025, with specific changes detailed in attached exhibits. The filing does not disclose any financial amounts or performance metrics, and no negative or flat performance data is mentioned.

• · The amendment was executed on June 24, 2026, and filed on June 30, 2026.
• · The original Master Repurchase Agreement was dated May 23, 2025.
• · The amendment includes modifications to the existing agreement as set forth in Exhibit A, which is attached but not fully detailed in the filing.
• · The amendment is governed by the laws of the State of New York.
• · The Guarantor reaffirmed its obligations under the Guaranty.
• · No financial terms, amounts, or performance metrics are disclosed in this filing.

30-06-2026

Patrick Industries (PATK) and LCI Industries (LCII) announced a definitive all-stock merger agreement to create a premier component solutions provider for outdoor enthusiast, housing, and transportation markets. Patrick shareholders will own approximately 52% of the combined company, with expected pro forma revenue of $8.1B and adjusted EBITDA of $1.0B inclusive of $150M+ in run-rate cost synergies. The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals.

• · Exchange ratio: LCI shareholders will receive 1.2440 shares of Patrick common stock for each LCI share.
• · Pro forma net leverage expected at 2.1x, with a target range of 2.25x to 2.5x.
• · Combined company will be headquartered in Elkhart, Indiana.
• · Transaction expected to close in first half of 2027.
• · Synergies identified in procurement, SG&A, engineering, and supply chain management.
• · Combined company will have a balanced dividend policy and share repurchase program as part of capital allocation.

30-06-2026

Seadrill Ltd issued $700 million in 6.750% Senior Notes due 2034, using proceeds to redeem its 8.375% Senior Secured Second Lien Notes due 2030 and amend its revolving credit facility, increasing commitments from $225 million to $300 million. The refinancing reduces interest cost and extends maturities, but adds leverage with new debt.

• · The new Notes mature on July 15, 2034, with interest payable semi-annually on January 15 and July 15, starting January 15, 2027.
• · The Issuer may redeem up to 40% of the original aggregate principal amount of the Notes with net cash proceeds from equity offerings before July 15, 2029, at 106.750% of principal.
• · The Indenture contains covenants restricting incurrence of additional debt, liens, distributions, asset sales, affiliate transactions, and mergers, subject to exceptions and suspension if the Notes achieve investment grade ratings from at least two rating agencies.
• · Upon a Change of Control Triggering Event, the Issuer must offer to repurchase the Notes at 101% of principal plus accrued interest.
• · The revolving credit facility under the Credit Agreement has not been drawn to date.

30-06-2026

Imunon, Inc. announced the retirement of interim CFO Jeffrey Church effective July 1, 2026, and the appointment of Josh Blacher as his successor under a consulting agreement with Danforth Health, Inc. Mr. Church will remain as a consultant for a $10,000 monthly retainer. The transition is described as amicable with no disagreements with management.

• · Josh Blacher, age 54, has been an employee of Danforth Health since September 2022 and Managing Partner of Columbus Circle Capital LLC since August 2019.
• · Mr. Blacher holds a BA in Economics from Yeshiva University and an MBA in Finance from Columbia Business School.
• · The consulting agreement with Mr. Church can be terminated upon 2 business days' notice.
• · Mr. Blacher has no family relationship with any director or executive officer of Imunon and no material interest in any reportable transaction.

30-06-2026

Worthington Steel, Inc. entered into a Credit Agreement dated June 25, 2026 with Wells Fargo Bank as administrative agent and several other lenders as joint lead arrangers. The agreement establishes a revolving credit facility with borrowing base determined by eligible receivables and inventory, with applicable margins ranging from 1.250% to 1.375% for SOFR loans based on average excess availability. The facility is secured by ABL Priority Collateral and coordinates with the company's existing 7.750% Senior Secured Notes due 2033 issued on June 1, 2026 and a separate intercreditor agreement also dated as of the closing date.

• · The Credit Agreement was signed June 25, 2026, two days before filing date of June 30, 2026.
• · Acquisition closing date referenced as June 3, 2026, indicating a recent acquisition occurred before this credit agreement.
• · The 2033 Senior Secured Notes were issued under an indenture dated June 1, 2026.
• · Borrowing base is subject to Advance Rates (not specified in excerpt) on eligible accounts receivable and inventory.
• · The facility includes a 'KLöckner Commitments' condition precedent, suggesting a portion of commitments tied to a specific acquisition or entity.
• · Alternative currency available only for Canadian Dollars.
• · Interest rate options: SOFR Loans and Base Rate Loans, plus a Term SOFR Option.
• · Typical negative covenants included: restrictions on Indebtedness, Liens, Investments, fundamental changes, asset dispositions, restricted payments, transactions with affiliates, and sale-leasebacks.
• · Financial covenant requires compliance measurement (covenant not detailed in excerpt).
• · Events of default include cross-default on other Indebtedness, Change in Control, bankruptcy, ERISA events, and judgment defaults.

30-06-2026

Perrigo Company plc appointed Salman Amin and Omer Gajial as independent directors effective June 30, 2026. Both bring deep experience in consumer products, retail, and digital transformation, which the Board expects to support the company's strategic priorities. No financial metrics or performance data were disclosed in this filing.

• · Salman Amin most recently served as CEO of pladis Global, leading a multi-year transformation with sustained revenue growth and improved profitability.
• · Omer Gajial currently serves as CEO of GoTo Foods, a franchisor and operator of more than 7,000 restaurant and retail locations globally.
• · Prior to GoTo Foods, Gajial was EVP and Chief Merchandising & Digital Officer at Albertsons Companies.
• · Amin previously held senior leadership roles at PepsiCo and Procter & Gamble, and served as COO of the Global Commercial Division at SC Johnson.

30-06-2026

Nuvectis Pharma announced a proposed underwritten public offering of its common stock to fund development of its pipeline candidates NXP100, NXP200, and NXP900. The offering is subject to market conditions, with Cantor acting as sole book runner, and net proceeds will also support hiring, capital expenditures, and general corporate purposes. No specific offering size or pricing terms were disclosed, and there is no assurance the offering will be completed.

• · The offering is made under an effective shelf registration statement on Form S-3 (File No. 333-293459) filed February 13, 2026 and declared effective February 20, 2026.
• · Cantor Fitzgerald & Co. is the sole book runner for the offering.
• · The underwriters have a 30-day option to purchase up to an additional 15% of the shares offered.
• · Nuvectis is a clinical-stage biopharmaceutical company focused on immune complement-related conditions and oncology.
• · NXP100 is described as a late-stage Factor B inhibitor with best-in-class potential and once-daily oral dosing.
• · NXP200 targets BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors including CNS cancer, colorectal cancer, melanoma, and NSCLC.
• · NXP900 inhibits both catalytic and scaffolding functions of SRC kinase.

30-06-2026

ChronoScale Corporation (formerly EKSO BIONICS HOLDINGS, INC.) expanded its board from seven to eight members and appointed Andrew Cordell Schaap as a director, effective June 29, 2026. Mr. Schaap also joined the Audit Committee (replacing Douglas Miller) and the Related Party Transactions Committee. He received a restricted stock award of 200,000 shares vesting in two equal annual installments. The filing also details the final committee assignments for the board.

• · The company's subsidiary is party to a data center lease with a company where Mr. Schaap serves as CEO and board member; the lease was entered into in the ordinary course of business.
• · Board committees established: Audit, Compensation, Nominating and Governance, and Related Party Transaction.
• · Committee chairs: Richard Nottenburg (Compensation), Ella Benson (Nominating and Governance), William M. Clancy (Audit and Related Party Transactions).
• · The restricted stock award vests in two equal annual installments on the first two anniversaries of the grant date, subject to continued service.
• · The filing is made under the name ChronoScale Corporation, indicating a possible name change from EKSO BIONICS HOLDINGS, INC.

30-06-2026

REalloys Inc. (BLBX) announced the resignation of CFO Robert Winspear effective June 24, 2026, with a severance package including $200,000 cash and 20,000 restricted shares. The company appointed Craig Cunningham as CFO via a consulting agreement with Provenance Advisors, with a base fee of $55,000/month ($660,000 annualized) and a target bonus of 100% of base. Additionally, director Joseph Sawyer resigned effective June 29, 2026, and the board does not plan to fill the vacancy. The changes are not due to any disagreements with the company.

• · Outgoing CFO Robert Winspear's resignation was not due to any disagreement with the company.
• · New CFO Craig Cunningham, age 43, previously served as CFO of Li-Cycle Holdings Corp. (March 2024 to April 2025) and Electra Battery Materials Corporation (June 2022 to July 2023).
• · Craig Cunningham will provide CFO services through Provenance Advisors as an independent contractor.
• · The consulting agreement automatically renews for successive 12-month terms unless either party gives 90 days' notice.
• · New CFO is eligible for annual equity refresh awards in subsequent years.
• · Director Joseph Sawyer resigned effective June 29, 2026, and the board does not intend to fill the vacancy.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

30-06-2026

Fox Corporation entered into a $1,000,000,000 term loan credit agreement dated June 30, 2026, with Morgan Stanley Senior Funding, Inc. as administrative agent and joint lead arranger alongside Citibank, Deutsche Bank, Goldman Sachs, and JPMorgan Chase. The proceeds will be used to finance the acquisition of a target company (the 'Acquired Business') under a merger agreement dated June 14, 2026. The credit agreement includes financial covenant requirements based on Adjusted Operating Income and a leverage ratio.

• · The credit agreement has a facility size of $1,000,000,000 (original amount) with joint lead arrangers including Morgan Stanley, Citibank, Deutsche Bank, Goldman Sachs, and JPMorgan Chase.
• · Interest rate margins range from 0.875% (Term SOFR) at highest credit rating to 1.375% at lowest; Base Rate margins range from 0.000% to 0.375%.
• · Commitment fee rates range from 0.070% to 0.175% per annum based on public debt ratings.
• · The acquisition target is acquired under an Agreement and Plan of Merger dated June 14, 2026, and the transaction is expected to close subject to conditions precedent including solvency certificate delivery.

30-06-2026

Verizon Master Trust issued $1.2B in asset-backed notes (Series 2026-2) across four tranches on June 30, 2026, with a combined initial balance of $1,200,000,000. The largest tranche, Class A-1a, accounts for $994,210,000 of the total. The filing includes executed agreements such as the Indenture and Series 2026-2 Account Control Agreement. No period-over-period comparisons are available as this is a single issuance event.

• · The Notes were issued under a final prospectus dated June 25, 2026.
• · The Indenture was between Verizon Master Trust and U.S. Bank Trust Company, National Association, as indenture trustee and note paying agent.
• · The Series 2026-2 Account Control Agreement was among the Trust, U.S. Bank Trust Company, National Association, as secured party, and U.S. Bank National Association, as financial institution.
• · References to previous filings include amendments from 2021 through 2025, indicating an ongoing structured finance program.
• · The Notes are asset-backed securities secured by receivables of the Trust.
• · Class A-1a notes represent 82.85% of the total issuance; Class A-1b: 6.25%; Class B: 6.81%; Class C: 4.09%.

30-06-2026

International Battery Metals Ltd. dismissed CBIZ CPAs as its independent auditor and engaged Grant Thornton LLP for the fiscal year ending March 31, 2027, effective June 24, 2026. The change was approved by the Audit Committee and was not due to any disagreements on accounting principles. However, the filing discloses a prior material weakness in internal controls over capital asset capitalization and useful lives, which was subsequently remediated during fiscal 2026.

• · CBIZ CPAs' reports for fiscal years ended March 31, 2026 and 2025 were unqualified, containing no adverse opinion or disclaimer.
• · A material weakness in internal control over financial reporting was identified during fiscal 2025, related to capitalization of capital assets and determination of useful lives.
• · The material weakness was remediated during fiscal 2026, as disclosed in the Annual Report on Form 10-K.
• · No consultations occurred with Grant Thornton prior to engagement regarding accounting principles or audit opinions.